These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 30116828)

  • 1. Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1653-1662. PubMed ID: 30116828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
    Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
    Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Safety and Effectiveness of Reduced Doses of Direct Acting Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.
    Skjøth F; Larsen TB; Dun AR; Lilja M; Rahman I; Abdelgawwad K; Halvorsen S; Coleman C; Rivera M
    Am J Med; 2024 Jun; 137(6):520-528.e13. PubMed ID: 38387539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of Patients With Ischemic Stroke With Prior Anticoagulant Therapy: Direct Oral Anticoagulants Versus Warfarin.
    Chun KH; Lee H; Hong JH; Seo KD
    J Am Heart Assoc; 2024 Aug; 13(15):e034698. PubMed ID: 39101509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
    Gundlund A; Staerk L; Fosbøl EL; Gadsbøll K; Sindet-Pedersen C; Bonde AN; Gislason GH; Olesen JB
    J Intern Med; 2017 Aug; 282(2):164-174. PubMed ID: 28480507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.
    Lutsey PL; Norby FL; Ensrud KE; MacLehose RF; Diem SJ; Chen LY; Alonso A
    JAMA Intern Med; 2020 Feb; 180(2):245-253. PubMed ID: 31764956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
    Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
    Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
    Shah S; Norby FL; Datta YH; Lutsey PL; MacLehose RF; Chen LY; Alonso A
    Blood Adv; 2018 Feb; 2(3):200-209. PubMed ID: 29378726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints.
    Zielinski GD; Teichert M; Klok FA; Rosendaal FR; Huisman MV; Cannegieter SC; Lijfering WM
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1371-1378. PubMed ID: 30443944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.